SCHEMBL5536205

SCHEMBL5536205

CCCOC(=O)N1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.62
LMNA P02545 4/20 0.62
GAA P10253 3/20 0.62
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 7/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
HTT P42858 2/20 0.53
MAPK1 P28482 1/20 0.53
HPGD P15428 2/20 0.49
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 1/20 0.48
PDE3B Q13370 1/20 0.44
PDE3A Q14432 1/20 0.44
USP2 O75604 1/20 0.44
POLB P06746 1/20 0.43
CHRM4 P08173 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539965 0.92 MAPT (0.59) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5541807 0.90 MAPT (0.58) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5542804 0.89 MAPT (0.77) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5535574 0.89 MAPT (0.57) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5536209 0.88 MAPT (0.81) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL13514056 0.87 MAPT (0.61) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL24641954 0.82 MAPT (0.83) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5539971 0.80 MAPT (0.76) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5544806 0.80 L3MBTL1 (0.73) MAPTLMNAGAAKDM4EALDH1A1
SCHEMBL5541814 0.79 MAPT (0.74) MAPTLMNAGAAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885LMNA 4152/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.